Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: J Affect Disord. 2011 May 4;132(3):422–431. doi: 10.1016/j.jad.2011.03.052

Figure 5.

Figure 5

Micrographs of a typical arrangement (top and bottom) of ICAM-1 immunoreactivity (green in A) in relation to GFAP-IR (red in B) astrocytes obtained simultaneously using antibodies to ICAM-1 and the astrocytic marker GFAP in a 70 year-old subject with MDD. Note in C (yellow areas, arrowheads) that the patches of diffuse ICAM-1 immunoreactivity (green in A) are largely confined within the area affected by GFAP-IR processes (red in B). ICAM-1 immunoreactivity (green in A and C, arrow) is also observable in structures with the morphology of blood vessels.